Neuroprotective effects of Bacopa monnieri in Parkinson's disease model

Singh B, Pandey S, Rumman M, Mahdi AA.

Metab Brain Dis. 2020 Mar;35(3):517-525. doi: 10.1007/s11011-019-00526-w. Epub 2019 Dec 13.

Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers of Idiopathic Parkinson's Disease

Cressatti M, Juwara L, Galindez JM, Velly AM, Nkurunziza ES, Marier S, Canie O, Gornistky M, Schipper HM.

Mov Disord. 2020 Mar;35(3):468-477. doi: 10.1002/mds.27935. Epub 2019 Dec 4.

NF-κB-Mediated Neuroinflammation in Parkinson's Disease and Potential Therapeutic Effect of Polyphenols

Singh SS, Rai SN, Birla H, Zahra W, Rathore AS, Singh SP.

Neurotox Res. 2020 Mar;37(3):491-507. doi: 10.1007/s12640-019-00147-2. Epub 2019 Dec 10.

Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease

Ravanidis S, Bougea A, Papagiannakis N, Maniati M, Koros C, Simitsi AM, Bozi M, Pachi I, Stamelou M, Paraskevas GP, Kapaki E, Moraitou M, Michelakakis H, Stefanis L, Doxakis E.

Mov Disord. 2020 Mar;35(3):457-467. doi: 10.1002/mds.27928. Epub 2019 Dec 4.

Characterization of novel conformation-selective α-synuclein antibodies as potential immunotherapeutic agents for Parkinson's disease

Henderson MX, Covell DJ, Chung CH, Pitkin RM, Sandler RM, Decker SC, Riddle DM, Zhang B, Gathagan RJ, James MJ, Trojanowski JQ, Brunden KR, Lee VMY, Luk KC.

Neurobiol Dis. 2020 Mar;136:104712. doi: 10.1016/j.nbd.2019.104712. Epub 2019 Dec 16.

The role of virtual reality on outcomes in rehabilitation of Parkinson's disease: meta-analysis and systematic review in 1031 participants

Triegaardt J, Han TS, Sada C, Sharma S, Sharma P.

Neurol Sci. 2020 Mar;41(3):529-536. doi: 10.1007/s10072-019-04144-3. Epub 2019 Dec 6.

Association of genetic variants within HLA-DR region with Parkinson's disease in Taiwan

Chang KH, Wu YR, Chen YC, Fung HC, Chen CM.

Neurobiol Aging. 2020 Mar;87:140.e13-140.e18. doi: 10.1016/j.neurobiolaging.2019.11.002. Epub 2019 Nov 9.

Alterations of regional homogeneity in Parkinson's disease with mild cognitive impairment: a preliminary resting-state fMRI study

Li MG, Liu TF, Zhang TH, Chen ZY, Nie BB, Lou X, Wang ZF, Ma L.

Neuroradiology. 2020 Mar;62(3):327-334. doi: 10.1007/s00234-019-02333-7. Epub 2019 Dec 10.

Frequency of non-motor symptoms and their impact on the quality of life in patients with Parkinson's disease: a prospective descriptive case series

Gulunay A, Cakmakli GY, Yon MI, Ulusoy EK, Karakoc M.

Psychogeriatrics. 2020 Mar;20(2):206-211. doi: 10.1111/psyg.12489. Epub 2019 Nov 28.

Improvement of oral function and hygiene in Parkinson's disease: A randomised controlled clinical trial

Baram S, Karlsborg M, Bakke M.

J Oral Rehabil. 2020 Mar;47(3):370-376. doi: 10.1111/joor.12924. Epub 2020 Jan 5.

No genetic evidence for involvement of alcohol dehydrogenase genes in risk for Parkinson's disease

Kim JJ, Bandres-Ciga S, Blauwendraat C; International Parkinson's Disease Genomics Consortium, Gan-Or Z.

Neurobiol Aging. 2020 Mar;87:140.e19-140.e22. doi: 10.1016/j.neurobiolaging.2019.11.006. Epub 2019 Nov 14.

Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study.

Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S; COPARK Study Group..

Drugs Aging. 2020 Mar;37(3):215-223. doi: 10.1007/s40266-019-00740-2.

What predicts quality of life after subthalamic deep brain stimulation in Parkinson's disease? A systematic review

Geraedts VJ, Feleus S, Marinus J, van Hilten JJ, Contarino MF.

Eur J Neurol. 2020 Mar;27(3):419-428. doi: 10.1111/ene.14147. Epub 2020 Jan 24.

Differences in cognitive profiles between Lewy body and Parkinson's disease dementia.

Martini A, Weis L, Schifano R, Pistonesi F, Fiorenzato E, Antonini A, Biundo R.

J Neural Transm (Vienna). 2020 Mar;127(3):323-330. doi: 10.1007/s00702-019-02129-2. Epub 2020 Jan 2.

Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease

Koutzoumis DN, Vergara M, Pino J, Buddendorff J, Khoshbouei H, Mandel RJ, Torres GE.

Exp Neurol. 2020 Mar;325:113159. doi: 10.1016/j.expneurol.2019.113159. Epub 2019 Dec 13.